Zymeworks Inc. (NYSE:ZYME) Director Buys $825,315.48 in Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 73,953 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were bought at an average price of $11.16 per share, with a total value of $825,315.48. Following the completion of the transaction, the director now owns 17,773,727 shares of the company's stock, valued at $198,354,793.32. The trade was a 0.42 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The stock was purchased at an average cost of $11.17 per share, for a total transaction of $2,194,212.46.
• On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The shares were purchased at an average cost of $11.85 per share, with a total value of $881,166.00.
• On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The shares were purchased at an average price of $11.75 per share, for a total transaction of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc bought 43,848 shares of Zymeworks stock. The stock was purchased at an average price of $12.24 per share, with a total value of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock. The shares were acquired at an average price of $13.08 per share, for a total transaction of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock. The stock was acquired at an average price of $12.78 per share, with a total value of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was acquired at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were acquired at an average price of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was bought at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were bought at an average price of $11.49 per share, with a total value of $3,684,728.10.

Zymeworks Price Performance

ZYME stock traded up $0.29 during trading on Wednesday, reaching $12.45. The company had a trading volume of 520,409 shares, compared to its average volume of 619,983. The business has a 50 day moving average of $12.22 and a 200 day moving average of $13.51. The company has a market cap of $866.23 million, a P/E ratio of -8.30 and a beta of 1.18. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70.

Analyst Ratings Changes

A number of research firms have recently weighed in on ZYME. HC Wainwright increased their price objective on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th. Citigroup increased their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. Finally, Lifesci Capital started coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zymeworks presently has a consensus rating of "Moderate Buy" and an average price target of $21.00.

Hedge Funds Weigh In On Zymeworks

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after buying an additional 1,525 shares during the period. Stifel Financial Corp grew its holdings in Zymeworks by 2.1% in the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock worth $924,000 after purchasing an additional 1,540 shares during the period. State Street Corp grew its holdings in Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares during the period. Jane Street Group LLC boosted its position in shares of Zymeworks by 27.3% in the 3rd quarter. Jane Street Group LLC now owns 80,326 shares of the company's stock worth $1,008,000 after purchasing an additional 17,205 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Zymeworks by 476.3% in the 3rd quarter. Barclays PLC now owns 154,384 shares of the company's stock worth $1,937,000 after buying an additional 127,595 shares during the last quarter. Institutional investors own 92.89% of the company's stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.